{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:42:07Z","timestamp":1740163327736,"version":"3.37.3"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001677","name":"National Institute of Health","doi-asserted-by":"publisher","award":["CA183615","AI110261"],"award-info":[{"award-number":["CA183615","AI110261"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Margaret E. Early Medical Research Trust"},{"DOI":"10.13039\/501100001677","name":"National Institute of Health","doi-asserted-by":"publisher","award":["5T32AI060567"],"award-info":[{"award-number":["5T32AI060567"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.coviro.2015.08.005","type":"journal-article","created":{"date-parts":[[2015,9,10]],"date-time":"2015-09-10T01:31:16Z","timestamp":1441848676000},"page":"62-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["High-resolution genetic profile of viral genomes: why it matters"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7822-781X","authenticated-orcid":false,"given":"Hangfei","family":"Qi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas C","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushen","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2015.08.005_bib0445","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.coviro.2015.08.005_bib0450","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1126\/science.290.5498.1972","article-title":"Efficient initiation of HCV RNA replication in cell culture","volume":"290","author":"Blight","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.coviro.2015.08.005_bib0455","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1126\/science.1114016","article-title":"Complete replication of hepatitis C virus in cell culture","volume":"309","author":"Lindenbach","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.coviro.2015.08.005_bib0460","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2015.08.005_bib0465","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1073\/pnas.0510727103","article-title":"Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells","volume":"103","author":"Yi","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.08.005_bib0470","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.molmed.2014.02.002","article-title":"Hepatitis C treatment: an incipient therapeutic revolution","volume":"20","author":"deLemos","year":"2014","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.coviro.2015.08.005_bib0475","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jac\/dkr215","article-title":"Directly acting antivirals against hepatitis C virus","volume":"66","author":"Soriano","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coviro.2015.08.005_bib0480","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.08.005_bib0485","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.08.005_bib0490","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.08.005_bib0495","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.08.005_bib0500","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coviro.2014.04.008","article-title":"Resistance to hepatitis C virus protease inhibitors","volume":"8","author":"Kieffer","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2015.08.005_bib0505","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","article-title":"Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study","volume":"58","author":"Fried","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2015.08.005_bib0510","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jhep.2012.10.028","article-title":"Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202)","volume":"58","author":"Lenz","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2015.08.005_bib0515","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","author":"Lam","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2015.08.005_bib0520","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1128\/JVI.01360-09","article-title":"Identification of Hepatitis C virus NS5A inhibitors","volume":"84","author":"Lemm","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.08.005_bib0525","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2015.08.005_bib0530","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2015.08.005_bib0535","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1128\/AAC.05977-11","article-title":"Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052","volume":"56","author":"Wang","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2015.08.005_bib0540","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1128\/AAC.06169-11","article-title":"In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A","volume":"56","author":"Wang","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2015.08.005_bib0545","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrgastro.2015.53","article-title":"Treatment of hepatitis C in difficult-to-treat patients","volume":"12","author":"Ferenci","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.coviro.2015.08.005_bib0550","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.08.005_bib0555","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.08.005_bib0560","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.08.005_bib0565","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.08.005_bib0570","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2015.08.005_bib0575","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrc3297","article-title":"Managing drug resistance in cancer: lessons from HIV therapy","volume":"12","author":"Bock","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.coviro.2015.08.005_bib0580","doi-asserted-by":"crossref","first-page":"e1002881","DOI":"10.1371\/journal.ppat.1002881","article-title":"Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate","volume":"8","author":"Ribeiro","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2015.08.005_bib0585","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1128\/JVI.00201-09","article-title":"Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo","volume":"83","author":"Cuevas","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.08.005_bib0590","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.coviro.2015.08.005_bib0595","doi-asserted-by":"crossref","first-page":"ra3230","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"Rong","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2015.08.005_bib0600","doi-asserted-by":"crossref","first-page":"10290","DOI":"10.1073\/pnas.1101515108","article-title":"Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals","volume":"108","author":"Robinson","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.08.005_bib0605","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.coviro.2011.10.001","article-title":"Resistance to anti-HCV protease inhibitors","volume":"1","author":"Thompson","year":"2011","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2015.08.005_sbref0610","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nmeth.3027","article-title":"Deep mutational scanning: a new style of protein science","volume":"11","author":"Fowler","year":"2014","journal-title":"Nat Methods"},{"key":"10.1016\/j.coviro.2015.08.005_bib0615","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/nprot.2014.153","article-title":"Measuring the activity of protein variants on a large scale using deep mutational scanning","volume":"9","author":"Fowler","year":"2014","journal-title":"Nat Protoc"},{"key":"10.1016\/j.coviro.2015.08.005_bib0620","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.2471267","article-title":"High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis","volume":"244","author":"Cunningham","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.coviro.2015.08.005_bib0625","doi-asserted-by":"crossref","first-page":"10220","DOI":"10.1128\/JVI.00793-07","article-title":"Alanine scanning of the hepatitis C virus core protein reveals numerous residues essential for production of infectious virus","volume":"81","author":"Murray","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.08.005_bib0630","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1101\/gr.220702","article-title":"Functional genomics on potato virus A: virus genome-wide map of sites essential for virus propagation","volume":"12","author":"Kekarainen","year":"2002","journal-title":"Genome Res"},{"key":"10.1016\/j.coviro.2015.08.005_bib0635","doi-asserted-by":"crossref","first-page":"e1000182","DOI":"10.1371\/journal.ppat.1000182","article-title":"High-resolution functional profiling of hepatitis C virus genome","volume":"4","author":"Arumugaswami","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2015.08.005_bib0640","doi-asserted-by":"crossref","first-page":"e1001146","DOI":"10.1371\/journal.ppat.1001146","article-title":"High-resolution functional mapping of the Venezuelan equine encephalitis virus genome by insertional mutagenesis and massively parallel sequencing","volume":"6","author":"Beitzel","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2015.08.005_bib0645","doi-asserted-by":"crossref","first-page":"11441","DOI":"10.1128\/JVI.00439-12","article-title":"High-resolution functional profiling of the norovirus genome","volume":"86","author":"Thorne","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.08.005_bib0650","doi-asserted-by":"crossref","first-page":"20248","DOI":"10.1073\/pnas.1320524110","article-title":"Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins","volume":"110","author":"Heaton","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.08.005_bib0655","first-page":"5","article-title":"A comprehensive functional map of the hepatitis C virus genome provides a resource for probing viral proteins","author":"Remenyi","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.coviro.2015.08.005_sbref0660","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12977-014-0124-6","article-title":"High-throughput profiling of point mutations across the HIV-1 genome","volume":"11","author":"Al-Mawsawi","year":"2014","journal-title":"Retrovirology"},{"key":"10.1016\/j.coviro.2015.08.005_bib0665","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1128\/JVI.01658-12","article-title":"Systematic identification of H274Y compensatory mutations in influenza A virus neuraminidase by high-throughput screening","volume":"87","author":"Wu","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.08.005_sbref0670","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1038\/srep04942","article-title":"High-throughput profiling of influenza A virus hemagglutinin gene at single-nucleotide resolution","volume":"4","author":"Wu","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2015.08.005_sbref0675","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/molbev\/msu173","article-title":"An experimentally determined evolutionary model dramatically improves phylogenetic fit","volume":"31","author":"Bloom","year":"2014","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.coviro.2015.08.005_sbref0680","first-page":"3","article-title":"The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin","author":"Thyagarajan","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.coviro.2015.08.005_bib0685","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nsmb.1779","article-title":"Structures of influenza A proteins and insights into antiviral drug targets","volume":"17","author":"Das","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.coviro.2015.08.005_bib0690","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrmicro2747","article-title":"The structural biology of HIV-1: mechanistic and therapeutic insights","volume":"10","author":"Engelman","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.coviro.2015.08.005_bib0695","first-page":"113","article-title":"Hepatitis C virus proteins: from structure to function","volume":"369","author":"Moradpour","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.coviro.2015.08.005_bib0700","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1126\/science.1171491","article-title":"Antibody recognition of a highly conserved influenza virus epitope","volume":"324","author":"Ekiert","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.coviro.2015.08.005_bib0705","doi-asserted-by":"crossref","first-page":"e3942","DOI":"10.1371\/journal.pone.0003942","article-title":"Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells","volume":"3","author":"Throsby","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2015.08.005_bib0710","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1202617","article-title":"Computational design of proteins targeting the conserved stem region of influenza hemagglutinin","volume":"332","author":"Fleishman","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.coviro.2015.08.005_sbref0715","doi-asserted-by":"crossref","first-page":"e1004064","DOI":"10.1371\/journal.ppat.1004064","article-title":"A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity","volume":"10","author":"Qi","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2015.08.005_bib0720","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations","volume":"54","author":"Fridell","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2015.08.005_bib0725","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","article-title":"Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options","volume":"58","author":"Suzuki","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2015.08.005_bib0730","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2013.10.057","article-title":"Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection","volume":"146","author":"Everson","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2015.08.005_bib0735","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2015.08.005_bib0740","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1128\/AAC.02068-13","article-title":"Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin","volume":"58","author":"Murakami","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2015.08.005_bib0745","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.08.005_bib0750","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/gutjnl-2014-307498","article-title":"Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study","volume":"64","author":"Hezode","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2015.08.005_bib0755","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2015.3868","article-title":"Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis","volume":"313","author":"Muir","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.coviro.2015.08.005_bib0760","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/jmv.24255","article-title":"Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy","volume":"87","author":"Yoshimi","year":"2015","journal-title":"J Med Virol"},{"key":"10.1016\/j.coviro.2015.08.005_bib0765","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1021\/ml300017p","article-title":"Discovery of MK-5172, a macrocyclic hepatitis C virus NS3\/4a protease inhibitor","volume":"3","author":"Harper","year":"2012","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.coviro.2015.08.005_bib0770","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/jm400121t","article-title":"Discovery of hepatitis C virus NS3-4A protease inhibitors with improved barrier to resistance and favorable liver distribution","volume":"57","author":"Moreau","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2015.08.005_bib0775","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00324-12","article-title":"MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants","volume":"56","author":"Summa","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2015.08.005_bib0780","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.antiviral.2009.10.003","article-title":"Fifteen years of HIV protease inhibitors: raising the barrier to resistance","volume":"85","author":"Wensing","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2015.08.005_bib0785","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1016\/j.bmc.2007.09.010","article-title":"Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV","volume":"15","author":"Ghosh","year":"2007","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.coviro.2015.08.005_bib0790","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","article-title":"Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced. HIV-infected patients in TITAN: a randomised controlled phase III trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2015.08.005_bib0795","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1046\/j.1469-0691.2003.00730.x","article-title":"New patterns of HIV-1 resistance during HAART","volume":"9","author":"Fumero","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.coviro.2015.08.005_bib0800","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1128\/AAC.01492-10","article-title":"Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment","volume":"55","author":"Liu","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2015.08.005_bib0805","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.aids.0000216370.69066.7f","article-title":"Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy","volume":"20","author":"Palmer","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2015.08.005_bib0810","first-page":"123","article-title":"Strategies for overcoming resistance in HIV-1 infected patients receiving HAART","volume":"6","author":"Clotet","year":"2004","journal-title":"AIDS Rev"},{"key":"10.1016\/j.coviro.2015.08.005_bib0815","doi-asserted-by":"crossref","first-page":"9530","DOI":"10.1073\/pnas.1105422108","article-title":"Detection and quantification of rare mutations with massively parallel sequencing","volume":"108","author":"Kinde","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.08.005_bib0820","doi-asserted-by":"crossref","first-page":"19872","DOI":"10.1073\/pnas.1319590110","article-title":"High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing","volume":"110","author":"Lou","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.08.005_bib0825","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1089\/aid.2014.0097","article-title":"Short communication: HIV-1 gag genetic variation in a single acutely infected participant defined by high-resolution deep sequencing","volume":"30","author":"Al-Mawsawi","year":"2014","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.coviro.2015.08.005_bib0830","doi-asserted-by":"crossref","first-page":"e97505","DOI":"10.1371\/journal.pone.0097505","article-title":"HIV-1 quasispecies delineation by tag linkage deep sequencing","volume":"9","author":"Wu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2015.08.005_bib0835","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1186\/s13059-014-0517-9","article-title":"BAsE-Seq: a method for obtaining long viral haplotypes from short sequence reads","volume":"15","author":"Hong","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.coviro.2015.08.005_bib0840","doi-asserted-by":"crossref","first-page":"i329","DOI":"10.1093\/bioinformatics\/btu295","article-title":"Accurate viral population assembly from ultra-deep sequencing data","volume":"30","author":"Mangul","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.coviro.2015.08.005_bib0845","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1471-2105-12-119","article-title":"ShoRAH: estimating the genetic diversity of a mixed sample from next-generation sequencing data","volume":"12","author":"Zagordi","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.coviro.2015.08.005_bib0850","doi-asserted-by":"crossref","first-page":"e1000074","DOI":"10.1371\/journal.pcbi.1000074","article-title":"Viral population estimation using pyrosequencing","volume":"4","author":"Eriksson","year":"2008","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.coviro.2015.08.005_bib0855","doi-asserted-by":"crossref","first-page":"7400","DOI":"10.1093\/nar\/gkq655","article-title":"Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies","volume":"38","author":"Zagordi","year":"2010","journal-title":"Nucleic Acids Res"},{"issue":"Suppl. 9","key":"10.1016\/j.coviro.2015.08.005_bib0860","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1471-2105-14-S9-S2","article-title":"Reconstruction of viral population structure from next-generation sequencing data using multicommodity flows","volume":"14","author":"Skums","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.coviro.2015.08.005_bib0865","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/bioinformatics\/btr627","article-title":"QuRe: software for viral quasispecies reconstruction from next-generation sequencing data","volume":"28","author":"Prosperi","year":"2012","journal-title":"Bioinformatics"},{"issue":"Suppl. 6","key":"10.1016\/j.coviro.2015.08.005_bib0870","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-2105-12-S6-S1","article-title":"Inferring viral quasispecies spectra from 454 pyrosequencing reads","volume":"12","author":"Astrovskaya","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.coviro.2015.08.005_sbref0875","doi-asserted-by":"crossref","first-page":"e1004040","DOI":"10.1371\/journal.pcbi.1004040","article-title":"Rational design and adaptive management of combination therapies for hepatitis C virus infection","volume":"11","author":"Ke","year":"2015","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.coviro.2015.08.005_bib0880","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"Poveda","year":"2014","journal-title":"Antiviral Res"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625715001157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625715001157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T08:35:16Z","timestamp":1572770116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625715001157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":88,"alternative-id":["S1879625715001157"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2015.08.005","relation":{},"ISSN":["1879-6257"],"issn-type":[{"type":"print","value":"1879-6257"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-resolution genetic profile of viral genomes: why it matters","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2015.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}